Recent news

Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics in patients with sepsis.

March 26, 2023

Hence, this important publication presents a great opportunity for NucleoCapture colums to be used for diagnostic purposes, where cell-free DNA fragments can be progressively removed from a patient’s blood using histone conjugated polymer beads and used to monitor post-treatment complications.

September 30, 2021

Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.

Santersus AG is proud to be recognized as a top innovator and to be granted a presentation slot at the transCampus Partnership 10 year Anniversary Event in London on February 13, 2023.

Minister President of Saxony, Michael Kretschmer honored the transCampus partnership and its success during his keynote speech at the anniversary celebration.

January 11, 2021

First patients is enrolled to First In-Human Clinical Trial of NucleoCapture®

December 2, 2021

Ethics Committees of two major clinics approved NucleoCapture to proceed with a clinical trial in Sepsic Patients

November 26, 2021

Santersus’ Shareholders Elect New Board Members

September 22, 2021

Santersus AG Confirms Attendance at BioTech Gate

September 1, 2021

Santersus Raises CHF 750 thousand in Family & Friends Round

1 2 3 >